Patents by Inventor Katarina FÄRNEGÅRDH

Katarina FÄRNEGÅRDH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity
    Patent number: 10512634
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound. The compound is useful in therapy, for the treatment of disorders mediated by HDAC6, such as autoimmune disorders, neurodegenerative disorders and hyperproliferative disorders, such as cancer.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: December 24, 2019
    Assignee: KANCERA AB
    Inventors: Johan Schultz, Jan Vågberg, Elisabeth Olsson, Katarina Färnegårdh, Mattias Jönsson, Kristin Hammer, Lars Krüger
  • BENZIMIDAZOLE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY
    Publication number: 20180110755
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound. The compound is useful in therapy, for the treatment of disorders mediated by HDAC6, such as autoimmune disorders, neurodegenerative disorders and hyperproliferative disorders, such as cancer.
    Type: Application
    Filed: May 11, 2015
    Publication date: April 26, 2018
    Inventors: Johan SCHULTZ, Jan VÅGBERG, Elisabeth OLSSON, Katarina FÄRNEGÅRDH, Mattias JÖNSSON, Kristin HAMMER, Lars KRÜGER
  • COMPOUNDS AND USE FOR TREATING CANCER
    Publication number: 20160214958
    Abstract: The present invention relates to certain 2,4-disubstituted quinoline derivatives, to their therapy, as well as to pharmaceutical compositions comprising said compounds. More specifically the invention relates to certain 2,4-disubstituted quinoline derivatives or pharmaceutical compositions comprising said compounds for the treatment of cancers characterized by overactive Ras and/or Rac or signalling pathway.
    Type: Application
    Filed: September 9, 2014
    Publication date: July 28, 2016
    Inventors: Katarina FÄRNEGÅRDH, Ylva GRAVENFORS, Patrik ERNFORS, Lars HAMMARSTRÖM, Satish KITAMBI